Notice of Postal Ballot - Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("Listing Regulations").
NOVARTIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novartis India Limited is seeking shareholder approval via postal ballot for the appointment of Ms. Gowree Gokhale as a Non-Executive and Independent Director for a 5-year term from April 1, 2026 to March 31, 2031. Ms. Gokhale was initially appointed as an Additional Director (Independent) effective April 1, 2026, and this appointment requires member ratification as per SEBI Listing Regulations. The appointment fills the vacancy created when Ms. Sandra Martyres' second term as Independent Director concludes on April 18, 2026. Ms. Gokhale is a distinguished solicitor with over 30 years of legal experience, previously co-leading the Pharma and Medical Devices practice at Nishith Desai Associates. She specializes in Intellectual Property, Data Protection, Consumer Protection, M&A, and Competition Law. The e-voting period runs from April 17, 2026 to May 16, 2026, with results to be declared by May 19, 2026.
Positive for governance - Ms. Gokhale's appointment ensures compliance with SEBI regulations requiring at least 6 directors and maintains board independence. Her pharma industry legal expertise is aligned with Novartis India's core business, which could benefit board decision-making on regulatory and IP matters.